Search
Imlunestrant
go.drugbank.com/drugs/DB19043ApprovedInvestigationalprogression on at least one line of endocrine therapy. … [A256828] In clinical trials, imlunestrant has been investigated as monotherapy and in combination with other drugs in breast cancer patients.[A256828]
Coagulation factor VII human
go.drugbank.com/drugs/DB13150ApprovedInvestigationalCoagulation factor VII is human serine protease type enzyme that is involved in the extrinsic coagulation cascade which results in blood clotting.
Mixtures: COFACT 250 IU/10 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADET, COFACT 500 IU/20 ML IV ENJEKSIYON IÇIN TOZ IÇEREN FLAKON, 1 ADETCategories: coagulation factor IX, II, VII and X in combinationSerplulimab
go.drugbank.com/drugs/DB17451ApprovedInvestigationalIt was first approved in China - where it is indicated for a number of different cancers[L52963] - and has since been approved in several southeast Asian countries. … Most recently, it was approved in the EU in February 2025 for the treatment of extensive-stage small cell lung cancer.[L52968,L52953]
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsNintedanib
go.drugbank.com/drugs/DB09079ApprovedInvestigational[A185237] As a chemotherapeutic agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and failed first-line chemotherapeutic options.[L8459] … being [Pirfenidone]) and as such is used as a first-line treatment following diagnosis to slow down the progressive loss of lung function.
Osteoarthritis of the Knee
go.drugbank.com/conditions/DBCOND0032623Synonyms: Osteoarthritis in the Knee, Osteoarthritis in the Knee JointMemantine
go.drugbank.com/drugs/DB01043ApprovedInvestigationalMemantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulation in Alzheimer's Disease [T556]. … In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or a disease-modifying therapy by the year 2025 [L5953, F4366
Categories: N-methyl-D-aspartate Receptor AntagonistProducts: ZAHARME IR, MEMANTIN 1A PHARMA 10MGElectrolyte imbalance
go.drugbank.com/conditions/DBCOND0015850Synonyms: Abnormalities in electrolytesN-acetyltyrosine
go.drugbank.com/drugs/DB11102ApprovedInvestigationalN-acetyltyrosine, also referred to as N-acetyl-L-tyrosine, is used in place of as a tyrosine precursor. [DB00135] is a non-essential amino acid with a polar side group. … It is typically administered as a source of nutritional support where oral nutrition is inadequate or cannot be tolerated.
Mixtures: Aminosyn II in Dextrose, Aminosyn II in DextroseSynonyms: L-N-acetyltyrosine, N-acetyl-L-tyrosineEntacapone
go.drugbank.com/drugs/DB00494ApprovedInvestigationalEntacapone is a selective, reversible catechol-O-methyl transferase (COMT) inhibitor for the treatment of Parkinson's disease. It is a member of the class of nitrocatechols. … of levodopa and a decarboxylase inhibitor.
Mixtures: LEVO/CA/EN 100/25/200 STD, LEVO/CA/EN 150/37.5/200STDSynonyms: (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide, N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamideLuliconazole
go.drugbank.com/drugs/DB08933ApprovedInvestigationalIt was approved by the FDA (USA) in November 2013 and is marketed under the brand name Luzu. Luliconazole is also approved in Japan. … Luliconazole is a topical antifungal agent that acts by unknown mechanisms but is postulated to involve altering the synthesis of fungi cell membranes.